4D Molecular Therapeutics (NasdaqGS:FDMT) FY Conference Transcript

Summary of 4D Molecular Therapeutics FY Conference Call Company Overview - Company: 4D Molecular Therapeutics (NasdaqGS:FDMT) - Focus: Redefining genetic medicines through durable disease-targeted therapeutics for large market diseases, particularly in retinal vascular diseases [2][24] Key Product: 4D-150 - Current Stage: Phase 3 clinical trials for wet Age-related Macular Degeneration (AMD) [3][24] - Upcoming Trials: Plans to initiate a Phase 3 trial for diabetic macular edema (DME) later in the year [2][24] - Mechanism: 4D-150 is designed as a backbone therapy providing lifelong anti-VEGF expression, utilizing the R100 capsid for robust delivery [6][7] Development and Safety - Development Support: Fully funded for pulmonology assets (4D-710 and 4D-725) through the CF Foundation and CIRM [4] - Safety Profile: Phase 1/2 trial data shows low incidence of intraocular inflammation (IOI), with no evidence of IOI beyond 6 months in AMD patients [15][16] Efficacy and Treatment Burden - Treatment Burden Reduction: In a hard-to-treat patient population, treatment burden was reduced by nearly 80%, from an expected 20 injections to an average of 4.3 over two years [19][20] - Visual Acuity: Remained stable and equivalent to aflibercept through the two-year period [20] - Broader Population Results: In a less severe patient population, a 92% reduction in treatment burden was observed, with 73% of patients being injection-free after 1.5 years [22][23] Market Opportunity and Commercialization - Cost of Goods: Estimated at less than $1,000 per vial, allowing for flexible pricing strategies [28] - Market Demand: Enrollment for Phase 3 trials completed in less than 12 months, indicating strong demand for the therapy [25][26] - Integration into Clinical Practice: Designed for seamless integration into existing retina clinics, utilizing intravitreal administration similar to current therapies [30] Regulatory and Future Plans - Regulatory Designations: Received RMAT designation from the FDA and PRIME designation from EMA [24] - Upcoming Milestones: Expect to share two-year data from the Phase 2 study and updates on enrollment in Phase 3 trials later this year [31][32] - Financial Position: Over $500 million in cash at the end of 2025, providing a runway into the second half of 2028 [33] Industry Context - Unmet Needs: 92%-94% of retina specialists identify sustained efficacy and increased durability as the top unmet needs in the field [10] - Competitive Landscape: Gene therapy is viewed as the most exciting potential treatment for wet AMD, with nearly 50% of specialists expressing interest [12][13] Conclusion - Vision for 4D-150: Positioned to transform the standard of care for large market retinal vascular diseases with a focus on safety, efficacy, and commercial viability [33]